<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.humanpathol.com//inpress?rss=yes"><title>Human Pathology - Articles in Press</title><description>Human Pathology RSS feed: Articles in Press. Well illustrated, with exceptional reproductions of photomicrographs and microscopic anatomy, this critical and authoritative journal 
offers great diversity of coverage in each issue. Regular features include original contributions, current topics and progress in anatomic 
pathology, case studies, book reviews and notices. Several issues each year combine symposia with the regular editorial features.</description><link>http://www.humanpathol.com//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2010 Published by Elsevier Inc.  </dc:rights><prism:publicationName>Human Pathology</prism:publicationName><prism:issn>0046-8177</prism:issn><prism:publicationDate>2010-02-08</prism:publicationDate><prism:copyright> © 2010 Published by Elsevier Inc.  </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709004092/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003979/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS004681770900402X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709004353/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817710000122/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003967/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003682/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003955/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709004055/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS004681770900375X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003761/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003773/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003931/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003943/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003992/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003621/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003657/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003669/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003736/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003918/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003311/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709002962/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709002998/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003219/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS004681770900330X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003323/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003347/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003359/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003360/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003530/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003542/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003554/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003578/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003591/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003608/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS004681770900361X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003694/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003700/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003049/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003190/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003207/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS004681770900327X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003281/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003293/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003335/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709002925/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003189/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003220/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709003232/abstract?rss=yes"/><rdf:li rdf:resource="http://www.humanpathol.com/article/PIIS0046817709002883/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709004092/abstract?rss=yes"><title>Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and β-catenin, Sox9, and osteocalcin immunostaining of 22 cases - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709004092/abstract?rss=yes</link><description>Summary: Mesenchymal chondrosarcoma, a rare malignant round cell and hyaline cartilage tumor, is most commonly intraosseous but can occur in extraskeletal sites. We intensively observed the morphology and applied Sox9 (master regulator of chondrogenesis), β-catenin (involved in bone formation, thought to inhibit chondrogenesis in a Sox9-dependent manner), and osteocalcin (a marker for osteoblastic phenotype) to 22 central nervous system and musculoskeletal mesenchymal chondrosarcoma. Cases of mesenchymal chondrosarcoma were retrieved and reviewed from our files. Immunohistochemistry and follow-up were obtained on mesenchymal chondrosarcoma and tumor controls. Twenty-two mesenchymal chondrosarcomas included 5 central nervous system (all female; mean age, 30.2; mean size, 7.8 cm; in frontal lobe [n = 4] and spinal cord [n = 1]) and 17 musculoskeletal (female-male ratio, 11:6; mean age, 31.1; mean size, 6.2 cm; 3 each of humerus and vertebrae; 2 each of pelvis, rib, tibia, neck soft tissue; one each of femur, unspecified bone, and elbow soft tissue). The hyaline cartilage in most tumors revealed a consistent linear progression of chondrocyte morphology, from resting to proliferating to hypertrophic chondrocytes. Sixty-seven percent of cases demonstrated cell death and acquired osteoblastic phenotype, cells positive for osteocalcin at the site of endochondral ossification. Small round cells of mesenchymal chondrosarcoma were negative for osteocalcin. SOX9 was positive in both components of 21 of 22 cases of mesenchymal chondrosarcoma. β-Catenin highlighted rare nuclei at the interface between round cells and hyaline cartilage in 35% cases. Control skull and central nervous system cases were compared, including chondrosarcomas and small cell osteosarcoma, the latter positive for osteocalcin in small cells. Mesenchymal chondrosarcoma demonstrates centrally located hyaline cartilage with a linear progression of chondrocytes from resting to proliferative to hypertrophic, which undergoes endochondral ossification, recapitulating growth plate cartilage and suggesting that this component of mesenchymal chondrosarcoma may be a differentiated (benign or metaplastic) component of a malignant metastasizing tumor. This hyaline cartilage component is morphologically different from cartilage of control chondrosarcoma. Mesenchymal chondrosarcoma can be separated from small cell osteosarcoma, using Sox 9 for cartilage and osteocalcin for osteoblastic phenotype. Rare nuclear β-catenin expression at the interface between hyaline cartilage and small round cells potentially implicates the APC/Wnt pathway during endochondral ossification in morphologically benign hyaline cartilage component of mesenchymal chondrosarcoma.</description><dc:title>Reappraisal of mesenchymal chondrosarcoma: novel morphologic observations of the hyaline cartilage and endochondral ossification and β-catenin, Sox9, and osteocalcin immunostaining of 22 cases - Corrected Proof</dc:title><dc:creator>Julie C. Fanburg-Smith, Aaron Auerbach, Jayson S. Marwaha, Zengfeng Wang, Elisabeth J. Rushing</dc:creator><dc:identifier>10.1016/j.humpath.2009.11.006</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-02-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-02-08</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003979/abstract?rss=yes"><title>Expression of nestin regarding to lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003979/abstract?rss=yes</link><description>Summary: Stem cell marker nestin has been reported to be activated in various neoplasms, and its expression is correlated with poor prognosis. However, nestin expression in non-small cell lung cancer still remains unclear. The present study aimed to investigate nestin expression in 52 tissue samples of non-small cell lung cancer by immunohistochemical staining and explore its correlation with some clinicopathologic characteristics. The associations of nestin with lymphatic vessel density, microvessel density, vascular endothelial growth factor, vascular endothelial growth factor-C, and cyclooxygenase-2 (COX-2) were further observed to determine the linkage between nestin and lymphangiogenesis. The results showed that nestin expressed in tumor cells of 45 samples. High nestin expression correlated significantly with poor differentiation (P = .007), adenocarcinoma (P = .000), N2 lymph node metastasis (P = .006), high microvessel density (P = .033), and lymphatic vessel density (P = .020). Multivariate analysis of N1 and N2 lymph node metastasis revealed a 1.086-fold increase in hazard ratio of N2 lymph node involvement (P = .011) in patients with high nestin expression in primary tumor. More important, multivariate analysis showed a significant correlation of lymphatic vessel density with nestin and vascular endothelial growth factor-C expression (P = .039 and P = .045), independent of vascular endothelial growth factor, COX-2, and other clinicopathologic characteristics. The results demonstrated that nestin expressed in most tumor cells of non-small cell lung cancer tissue and had a direct linkage to lymph node metastasis and tumor-induced lymphangiogenesis, independent of COX-2 signal pathway.</description><dc:title>Expression of nestin regarding to lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients - Corrected Proof</dc:title><dc:creator>Zhenguang Chen, Tao Wang, Honghe Luo, Yingrong Lai, Xuhui Yang, Fugui Li, Yiyan Lei, Chunhua Su, Xiuming Zhang, Bruce T. Lahn, Andy Peng Xiang</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.018</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-02-04</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-02-04</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS004681770900402X/abstract?rss=yes"><title>Creation of a fully digital pathology slide archive by high-volume tissue slide scanning - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS004681770900402X/abstract?rss=yes</link><description>Summary: Digital slide scanners for scanning glass slides are becoming increasingly popular because current scanners are fast enough and produce good enough images for diagnostic purposes, education, and research. Also, the price for storing vast amounts of data has decreased over the last years, and this trend is expected to continue. Where most laboratories use their scanners mainly for education and research with limited financial and technical implications, we decided to face the huge challenges of prospectively setting up a fully digital pathology slide archive, primarily aiming to optimize the preparation and running of clinicopathological conferences. In this article, we describe the setup of our digital archiving solution and discuss the technical challenges we had to overcome. To give insight in the performance of our digital archive, we provide some statistics as well. We also present our thoughts on future developments in the area of digital slide scanning.</description><dc:title>Creation of a fully digital pathology slide archive by high-volume tissue slide scanning - Corrected Proof</dc:title><dc:creator>André Huisman, Arnoud Looijen, Steven M. van den Brink, Paul J. van Diest</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.026</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-02-04</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-02-04</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709004353/abstract?rss=yes"><title>Prognostic role of β-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709004353/abstract?rss=yes</link><description>Summary: β-Catenin and p53 play key roles in tumorigenesis. The relationships between these 2 signaling pathways and their contribution to colorectal cancer metastatic progression have not been completely elucidated. We analyzed 141 cases of primary sporadic colorectal cancer, 45 matched metastases, and 80 samples of normal mucosa by immunohistochemistry on paraffin-embedded specimens. The expression profiles were also related to patients' clinicopathologic features and 5-year survival. In primary tumors, β-catenin immunoreactivity was nuclear (27%), predominantly membrane/cytosolic (46.0%) or negative (27%). This latter subgroup was strongly related to microsatellite instability, in particular to MLH-1 deficiency. Remarkably, β-catenin membrane/cytosolic expression in primary tumors was reduced in the corresponding matched metastases. p53 showed a significant increase in immunoreactivity in (66.7%), whereas it was negative in (33.3%) of tumors. When we considered the expression of both genes, the combination of negative β-catenin and positive p53 nuclear staining (21%) was strongly related to a higher frequency of liver metastases. Such an association was significantly related to a worse prognosis than any other combination. In a multivariate analysis, β-catenin and distant metastases were independent prognostic markers. We suggest that a combination of low β-catenin and high p53 expression in primary colorectal cancers may be a prognostic factor in predicting the progression of the disease, the occurrence of metastasis, and a more severe outcome.</description><dc:title>Prognostic role of β-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer - Corrected Proof</dc:title><dc:creator>Massimo Pancione, Nicola Forte, Alessandra Fucci, Lina Sabatino, Antonio Febbraro, Arturo Di Blasi, Bruno Daniele, Domenico Parente, Vittorio Colantuoni</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.019</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-02-04</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-02-04</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817710000122/abstract?rss=yes"><title>Treponema pallidum immunostain distinguishing syphilitic gastritis from Helicobacter pylori-associated gastritis—reply - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817710000122/abstract?rss=yes</link><description>We thank Drs Liu and Hameed for their interest in our study .   A case of secondary syphilis mimicking Helicobacter pylori-associated gastritis is presented. The definite diagnosis was only suspected after observing a cutaneous rash clinically consistent with secondary syphilis and was confirmed by the immunohistochemical demonstration of multiple spirochetes within the lamina propria in the gastric biopsy specimen.</description><dc:title>Treponema pallidum immunostain distinguishing syphilitic gastritis from Helicobacter pylori-associated gastritis—reply - Corrected Proof</dc:title><dc:creator>Gemma Martin-Ezquerra, Ramon M. Pujol</dc:creator><dc:identifier>10.1016/j.humpath.2010.01.004</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-02-01</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-02-01</prism:publicationDate><prism:section>CORRESPONDENCE</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003967/abstract?rss=yes"><title>Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003967/abstract?rss=yes</link><description>Summary: Bag-1 is an antiapoptotic protein with its altered expression and localization in malignancies. To clarify the role of Bag-1 in gastric carcinogenesis, its expression was examined by immunohistochemistry and in situ hybridization on a tissue microarray containing gastric carcinomas, adjacent nonneoplastic mucosa (NNM), adenomas, intestinal metaplasia (IM), or gastritis. Gastric carcinoma tissue and cell lines were studied for Bag-1 expression by Western blot and reverse transcriptase-polymerase chain reaction (RT-PCR). The results demonstrated that Bag-1 proteins were differentially expressed in the nucleus or cytosol of MKN28, AGS, MKN45, KATO-III, or HGC-27 cell lines, despite similar levels of messenger RNA (mRNA) expression. The Bag-1 mRNA overexpression was detectable in 73.3% of 15 gastric carcinomas without significant difference in its encoding products' levels. The nuclear Bag-1 expression gradually decreased from gastritis, IM, adenoma to carcinoma (P &lt; .05), and negatively correlated with lymphatic invasion or lymph node metastasis, cytoplasmic Bag-1 expression, negative parafibromin expression, and poor prognosis (P &lt; .05). Cytoplasmic Bag-1 was weakly immunoreactive in carcinomas, compared with gastritis (P &lt; .05), and positively associated with invasive depth and poor prognosis of the carcinoma (P &lt; .05). The positive rate of Bag-1 mRNA expression was higher in adjacent IMs than carcinomas or adjacent NNM (P &lt; .05). Bag-1 mRNA was expressed more in carcinomas from female patients than the male counterparts (P &lt; .05). There was a positive correlation of Bag-1 mRNA expression with invasive depth and venous invasion (P &lt; .05). Our study indicated that aberrant expression and subcellular distribution of Bag-1 might play an important role in the malignant transformation of gastric epithelial cells and should be considered as a biomarker for gastric carcinogenesis, subsequent progression, and prognosis.</description><dc:title>Nuclear or cytoplasmic localization of Bag-1 distinctly correlates with pathologic behavior and outcome of gastric carcinomas - Corrected Proof</dc:title><dc:creator>Hua-chuan Zheng, Xiao-yan Xu, Ya-nan Xing, Zheng-li Wei, Hiroyuki Takahashi, Shinji Masuda, Yasuo Takano</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.017</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-25</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-25</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003682/abstract?rss=yes"><title>Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003682/abstract?rss=yes</link><description>Silva's Diagnostic Renal Pathology is a unique—and quite successful—attempt to present the vast subject of renal pathology in encyclopedic fashion in a single volume. Beginning with a detailed explanation of basic renal anatomy and physiology, its 17 chapters proceed in a logical fashion to encompass medical renal disease, cystic and developmental diseases, transplant pathology, and even the spectrum of renal tumors. The chapter on renal tumors, by Drs Tickoo, Argani, and Amin, and the one on renal disease from the nephrologists' perspective help make this book unusually comprehensive.</description><dc:title>Corrected Proof</dc:title><dc:creator>Priti Lal</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.003</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-22</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-22</prism:publicationDate><prism:section>BOOK REVIEW</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003955/abstract?rss=yes"><title>Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003955/abstract?rss=yes</link><description>Summary: The prognosis and therapy for malignant ovarian germ cell tumors including embryonal carcinoma differ from those of other categories of ovarian tumors, making accurate diagnosis imperative for patient care. Because of its rarity, the protein markers and genomic alterations typifying primary ovarian embryonal carcinoma have not been fully characterized. The present study aims to establish a set of sensitive and specific protein markers useful for the diagnosis and delineation of ovarian embryonal carcinoma. Chromosomal 12p anomalies were analyzed by dual-color fluorescence in situ hybridization. In a series of 6 ovarian mixed germ cell tumors with a component of embryonal carcinomas, OCT4, CD30, SOX2, and glypican 3 expressions were analyzed immunohistochemically on formalin-fixed paraffin-embedded tissue specimens. The results were compared to 4 cases of mixed germ cell tumor that were originally mistaken for embryonal carcinoma. OCT4 marked the nuclei of 6 cases, among which 5 cases also showed glypican 3 expression indicative of an admixed yolk sac tumor component. SOX2 was positive in only 3 cases of embryonal carcinoma. In 1 case of mixed germ cell tumor containing embryonal carcinoma, embryoid bodies from a component of polyembryoma were demonstrated to be both OCT4 and CD30 positive. Two cases originally classified as embryonal carcinoma were OCT4 and CD30 negative and showed glypican 3 positivity. They were reclassified as solid variant of yolk sac tumor. Two other cases originally classified as embryonal carcinoma were OCT4 positive and CD30 negative and were classified as immature teratoma with neuroectodermal differentiation based on the immunohistochemical findings as well as morphologic features and were diagnosed as immature teratoma. Chromosome 12p alterations were identified in 5 of 6 cases of embryonal carcinomas. In summary, a panel of immunostains is more useful than a single biomarker in the differential diagnosis of ovarian germ cell tumors. Chromosome 12p fluorescence in situ hybridization combined with OCT4, CD30, and glypican 3 immunostains is useful in confirming the diagnosis of ovarian embryonal carcinoma.</description><dc:title>Morphologic, immunohistochemical, and fluorescence in situ hybridization study of ovarian embryonal carcinoma with comparison to solid variant of yolk sac tumor and immature teratoma - Corrected Proof</dc:title><dc:creator>Liang Cheng, Shaobo Zhang, Aleksander Talerman, Lawrence M. Roth</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.016</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-22</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-22</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709004055/abstract?rss=yes"><title>Primary gastrointestinal stromal tumor of the liver with PDGFRA gene mutation - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709004055/abstract?rss=yes</link><description>Summary: Gastrointestinal stromal tumor is a mesenchymal tumor with KIT or PDGFRA gene mutation, occurring primarily in the stomach and intestine and rarely outside the digestive tract. KIT-negative tumors with epithelioid cell morphology and PDGFRA mutation represent a minor subset of gastrointestinal stromal tumor. Here, we describe a case of gastrointestinal stromal tumor in the liver of a 70-year-old man. The tumor was shown to be completely limited within the liver by radiologic, intraoperative, and pathologic examinations. Histopathologically, the tumor showed epithelioid cell-type morphology and immunohistochemical expression of CD34 and protein kinase C θ but was negative for cytokeratin, EMA, S-100, and HMB-45. KIT protein expression was very faint, and we judged it as negative. Mutation analysis revealed the presence of PDGFRA gene mutation (V561D) at exon 12. These findings are essentially the same as those typically seen in ordinary KIT-negative epithelioid cell-type gastrointestinal stromal tumor of the digestive tract. Although KIT-negative gastrointestinal stromal tumor occurring outside the gastrointestinal tract is very rare, this entity should be considered as a potential primary hepatic neoplasm.</description><dc:title>Primary gastrointestinal stromal tumor of the liver with PDGFRA gene mutation - Corrected Proof</dc:title><dc:creator>Hidetaka Yamamoto, Yuichi Miyamoto, Yunosuke Nishihara, Aya Kojima, Masakazu Imamura, Keiji Kishikawa, Yukari Takase, Keisuke Ario, Yoshinao Oda, Masazumi Tsuneyoshi</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.016</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-22</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-22</prism:publicationDate><prism:section>CASE STUDY</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS004681770900375X/abstract?rss=yes"><title>Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS004681770900375X/abstract?rss=yes</link><description>Summary: Matrix metalloproteinase 11 (stromelysin-3) has recently been reported to play a key role in human tumor progression and poor clinical outcome. The aim of this study was to investigate the significance of matrix metalloproteinase 11 expression in gastric cancer. Using real-time quantitative reverse-transcription polymerase chain reaction analysis and immunohistochemistry, we studied matrix metalloproteinase 11 expression levels in non-malignant gastric tissues and in gastric cancer tissues. The association between matrix metalloproteinase 11 expression levels and tumor stage and grade, as well as metastatic potential, was analyzed. Our results show that matrix metalloproteinase 11 expression was significantly higher in gastric cancer specimens compared with nonmalignant tissues at both transcriptional and protein levels, indicating its positive role in the development of gastric cancer. In addition, increased matrix metalloproteinase 11 expression levels were associated with advanced-stage and high-grade tumors, suggesting its involvement in the progression of gastric cancer. More importantly, increased matrix metalloproteinase 11 expression in gastric cancer specimens was correlated with increased expression of IGF-1, a molecule known to stimulate the proliferation, enhanced survival, and migration of cancer cells. Our results demonstrate that matrix metalloproteinase 11 is a novel factor in the development and progression of gastric cancer and suggest that matrix metalloproteinase 11 is a marker for advanced gastric cancer.</description><dc:title>Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance - Corrected Proof</dc:title><dc:creator>Zhong-Sheng Zhao, Yong-Quan Chu, Zai-Yuan Ye, Yuan-Yu Wang, Hou-Quan Tao</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.010</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003761/abstract?rss=yes"><title>Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003761/abstract?rss=yes</link><description>Summary: Although clear cell adenocarcinoma have been described focally mimicking nephrogenic adenoma, we have identified a subset of clear cell adenocarcinoma that diffusely resembles nephrogenic adenoma (nephrogenic adenoma-like clear cell adenocarcinoma). Twelve classic clear cell adenocarcinomas of the bladder and urethra and 7 nephrogenic adenoma-like clear cell adenocarcinomas were compared to 10 nephrogenic adenomas. Classic clear cell adenocarcinomas and nephrogenic adenoma-like clear cell adenocarcinomas comprised 4 men and 15 women. The following features were seen in classic clear cell adenocarcinomas: nephrogenic adenoma-like clear cell adenocarcinomas: predominantly solid pattern (7/12:0/7), marked nuclear pleomorphism (7/12:1/7), prominent nucleoli (5/12:1/7), clear cytoplasm in 50% or greater of tumor (7/12:0/7), and necrosis (8/12:3/7), although the necrosis in nephrogenic adenoma-like clear cell adenocarcinomas was often focal and intraluminal. Both patterns of clear cell adenocarcinomas showed prominent hobnail features, although more pronounced in nephrogenic adenoma-like clear cell adenocarcinomas. Muscularis propria invasion was seen in 5 of 9 classic clear cell adenocarcinomas and 6 of 6 nephrogenic adenoma-like clear cell adenocarcinomas, where evaluable. Classic clear cell adenocarcinoma was associated with urothelial carcinoma (n = 2) and endometriosis (n = 1). The Ki-67 rate in clear cell adenocarcinomas ranged from 10% to 80% compared with 0% to 5% in nephrogenic adenoma. The following antibodies were not helpful in distinguishing nephrogenic adenoma-like clear cell adenocarcinoma from nephrogenic adenoma: CD10, estrogen receptor, p63, high-molecular-weight cytokeratin, and α-methylacyl coenzyme-A racemase. PAX2 expression was more frequent in nephrogenic adenoma (89%) compared to both patterns of clear cell adenocarcinoma (29%-32%). The key features discriminating between nephrogenic adenoma-like clear cell adenocarcinoma and nephrogenic adenoma include occasional clear cells, more prominent pleomorphism especially hyperchromatic enlarged nuclei, and extensive muscular invasion. Presence of mitoses and a high rate of Ki-67 expression in lesions resembling nephrogenic adenoma require clinical correlation, close follow-up, and repeat biopsy with more extensive sampling.</description><dc:title>Clear cell adenocarcinoma of the bladder and urethra: cases diffusely mimicking nephrogenic adenoma - Corrected Proof</dc:title><dc:creator>Mehsati Herawi, Peter A. Drew, Chin-Chen Pan, Jonathan I. Epstein</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.011</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003773/abstract?rss=yes"><title>Virtual 3D microscopy in pathology education - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003773/abstract?rss=yes</link><description>In the August issue of Human Pathology, Fred R. Dee provided a detailed overview of virtual microscopy in pathology education . As requested by the author, we would like to supplement his contribution by findings on the current speed and efficiency of virtual 3-dimensional (3D) microscopy, and by further trends in image distribution using common standards.</description><dc:title>Virtual 3D microscopy in pathology education - Corrected Proof</dc:title><dc:creator>Ralf Zwönitzer, Harald Hofmann, Albert Roessner, Thomas Kalinski</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.012</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>CORRESPONDENCE</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003931/abstract?rss=yes"><title>On being a pathologist—full circle - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003931/abstract?rss=yes</link><description>As is the case with so many things that have happened in my life, I did not intend to be a pathologist. Having realized at a fairly young age that I could not sing I gave up an early desire to be an opera singer and decided, before I entered college, to go to medical school. This was at a time when medicine was not a career embraced by young women and my uncle, a neurosurgeon, felt that it would be much more appropriate for me to become a nurse. During my years at Radcliffe College, he tried to persuade me that nursing was the career I should follow.</description><dc:title>On being a pathologist—full circle - Corrected Proof</dc:title><dc:creator>Deborah E. Powell</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.014</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>PERSPECTIVES IN PATHOLOGY</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003943/abstract?rss=yes"><title>Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003943/abstract?rss=yes</link><description>Summary: The purpose of this study was to confirm that the grading system for lymph vessel tumor emboli is a significant histologic outcome predictor for patients with invasive ductal carcinoma. The subjects of this study were 1042 invasive ductal carcinoma patients who did not receive neoadjuvant therapy. We classified all invasive ductal carcinomas according to the grading system for lymph vessel tumor emboli we devised, and performed multivariate analyses with well-known prognostic factors. Of 1042 carcinomas, 666, 250, 97, and 29 were classified according to the grading system for lymph vessel tumor emboli as grade 0 (no lymph vessel invasion), grade 1, grade 2, and grade 3, respectively. The univariate analyses showed that the difference in outcome between the group with grade 0 and the group with grade 1 was not significant, but that survival time was significantly shorter in the group of patients with grade 2 carcinomas than in the group with grade 1 carcinomas and significantly shorter in the group of patients with grade 3 carcinomas than in the group with grade 2 carcinomas. Multivariate analyses demonstrated that having a grade 2 or grade 3 carcinoma significantly increased the hazard rates for tumor recurrence and tumor-related death in the patients as a whole as well as in both the group of patients with nodal metastasis and the group without nodal metastasis. The grading system for lymph vessel tumor emboli is an excellent histologic grading system for predicting the outcome of patients with invasive ductal carcinoma of the breast.</description><dc:title>Grading system for lymph vessel tumor emboli: significant outcome predictor for invasive ductal carcinoma of the breast - Corrected Proof</dc:title><dc:creator>Takahiro Hasebe, Nao Okada, Motoki Iwasaki, Sadako Akashi-Tanaka, Takashi Hojo, Tatsuhiro Shibata, Yuko Sasajima, Histoshi Tsuda, Takayuki Kinoshita</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.015</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003992/abstract?rss=yes"><title>IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003992/abstract?rss=yes</link><description>Summary: Differentiating reactive mesothelial cells from metastatic carcinoma and malignant mesothelioma is critical in effusion cytology. Numerous immunohistochemical/cytochemical reports use various antibodies in effusion samples, and most antibodies differentiate metastatic adenocarcinoma from malignant mesothelioma, but no antibodies help distinguish malignant mesothelioma from reactive mesothelial cells. A mouse monoclonal antibody (IMP3/L523S) against KOC is a 580-amino acid oncofetal RNA-binding protein containing 4 K homology domains. IMP3/L523S has been identified in several human malignant tumors. The immunocytochemical staining profile of IMP3 was determined in 95% alcohol-fixed cytologic effusion specimens. A total of 229 cases of pleural and peritoneal effusion cytospecimens were evaluated for the study, including 39 benign effusions with reactive mesothelial cells and 190 metastatic malignant effusions. IMP3 immunoreactivity was observed in 2 (5.1%) of 39 cases of reactive mesothelial cells, 138 (72.6%) of 190 cases of malignant effusion, 4 (36.4%) of 11 cases of malignant mesothelioma, 106 (75.7%) of 140 cases of metastatic adenocarcinoma, and 8 (100%) of 8 cases of squamous cell carcinoma. The overall specificity for the diagnosis of malignancy was 94.9%, whereas the sensitivity was 72.6%. In the peritoneal effusions, the sensitivity for the diagnosis of metastatic adenocarcinoma to distinguish reactive mesothelial cells was 92.3%. In conclusion, IMP3 staining is present in many carcinomas and is not a useful marker for distinguishing between carcinomas arising in different organs. However, the IMP3 antibody is a highly specific marker for malignant lesions, and thus, IMP3 staining is useful for distinguishing neoplastic cells from reactive mesothelial cells in effusion samples.</description><dc:title>IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology - Corrected Proof</dc:title><dc:creator>Katsuhide Ikeda, Genshu Tate, Takao Suzuki, Takashi Kitamura, Toshiyuki Mitsuya</dc:creator><dc:identifier>10.1016/j.humpath.2009.04.030</dc:identifier><dc:source>Human Pathology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003621/abstract?rss=yes"><title>Enkephalin, its precursor, processing enzymes, and receptor as part of a local opioid network throughout the respiratory system of lung cancer patients - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003621/abstract?rss=yes</link><description>Summary: Evidence is accumulating regarding the local opioid regulation of physiologic respiratory functions. However, anatomical evidence for a local opioid network of the respiratory system is scarce. In this study, tissue samples from 12 lung cancer patients undergoing lobectomy or pneumonectomy were examined immunohistochemically for the expression of the opioid network components met-enkephalin, the respective precursor proenkephalin, the key processing enzymes prohormone convertases 1 and 2, carboxypeptidase E, and the δ opioid receptor in different areas of human lung. Colocalization of proenkephalin with met-enkephalin, prohormone convertase 1, prohormone convertase 2, and carboxypeptidase E was demonstrated by double-immunofluorescence confocal microscopy in alveolar macrophages, submucosal glands, cancerous cells, and pulmonary neuroendocrine cells of bronchial epithelium. Corresponding δ opioid receptor was identified on cells of all these functionally relevant anatomical structures and on substance P–immunoreactive sensory nerve fibers arborizing within bronchial epithelium. Our findings provide evidence of a local opioid network, that is, the exact anatomical localization of proenkephalin, its functionally active peptide met-enkephalin, and the key processing enzymes as well as corresponding δ opioid receptor, linked to functionally important structures of the respiratory system. These findings encourage future studies to examine the functional role of local opioid peptides within the respiratory system.</description><dc:title>Enkephalin, its precursor, processing enzymes, and receptor as part of a local opioid network throughout the respiratory system of lung cancer patients - Corrected Proof</dc:title><dc:creator>Malgorzata Krajnik, Michael Schäfer, Piotr Sobanski, Janusz Kowalewski, Elzbieta Bloch-Boguslawska, Zbigniew Zylicz, Shaaban A. Mousa</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.025</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-30</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-30</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003657/abstract?rss=yes"><title>Factitial soft tissue pseudotumor due to injection of anabolic steroids: a report of 3 cases in 2 patients - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003657/abstract?rss=yes</link><description>Summary: Traumatically induced inflammation or reactive processes are a relatively well-known phenomenon in both skin and soft tissue. These include panniculitides, fat necrosis, nodular fasciitis, and nonspecific fibrosis. Occasionally, traumatic reactions can be associated with factitial injury due to self-induced blunt trauma or injection of chemical agents. Factitial pseudotumors of soft tissue mimicking neoplasms and occurring in deep-seated locations are rare and not well recognized. We have had the opportunity to review a handful of cases over the years of soft tissue pseudotumors caused by self injection of steroids for the purposes of bodybuilding. Three of these cases in 2 patients are presented here. One patient developed a deep lateral thigh mass that was radiologically suspicious for sarcoma but upon core biopsy was found to be a lipogranulomatous reaction. The second patient had 2 masses occurring in the upper and lower extremity with an interval of 1 year between the two. This patient had both masses resected. The first had the appearance of a giant cell tumor with no immediately discernible foreign material. The second mass was initially presumed to be a metastasis from the upper extremity tumor and showed similar areas to the first specimen; however, it also had areas of obvious reactive features with foreign material. These features were found in the first tumor as well upon retrospective review. Both patients admitted to self injection of anabolic steroids after further history was sought by the clinicians. Deep soft tissue pseudosarcomas caused by injection of steroids are not well documented, and patient's reluctance to provide this information leads to difficulty in arriving at a correct diagnosis. Recognition of this possibility is important in avoiding incorrect diagnoses and unnecessary treatments.</description><dc:title>Factitial soft tissue pseudotumor due to injection of anabolic steroids: a report of 3 cases in 2 patients - Corrected Proof</dc:title><dc:creator>Ilan Weinreb, John R. Goldblum, Brian P. Rubin</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.001</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-30</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-30</prism:publicationDate></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003669/abstract?rss=yes"><title>Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003669/abstract?rss=yes</link><description>Summary: Adenocarcinomas of the biliary tract and gallbladder are aggressive tumors with a poor prognosis. Standard chemotherapy often offers minimal benefit. Because epidermal growth factor receptor and HER-2/neu antagonists have been successfully used in adenocarcinomas from other sites, their use in cholangiocarcinoma can be potentially beneficial. This study examines the epidermal growth factor receptor and HER-2/neu expression and the epidermal growth factor receptor gene copy number in biliary tract adenocarcinomas. Fifty-one formalin-fixed, paraffin-embedded cases of adenocarcinomas (26 intrahepatic, 19 extrahepatic, 6 gallbladder) were stained with monoclonal antibodies against epidermal growth factor receptor and HER-2/neu. Fluorescence in situ hybridization analysis was performed in 37 cases using probes directed against epidermal growth factor receptor and centromeric region of chromosome 7. Epidermal growth factor receptor expression was present in 41 (80%) cases, with moderate or strong epidermal growth factor receptor staining in 30 (59%) cases. HER-2/neu was positive in 2 (4%) cases. Fluorescence in situ hybridization analysis showed gain in epidermal growth factor receptor gene copy number in 17 (46%) tumors. Of the latter, 1 showed gene amplification, whereas all others showed gain in chromosome 7, indicating balanced polysomy. Epidermal growth factor receptor overexpression by immunohistochemistry correlated significantly with epidermal growth factor receptor copy number by fluorescence in situ hybridization (P = .02). HER2/neu expression is uncommon in these tumors.</description><dc:title>Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder - Corrected Proof</dc:title><dc:creator>Nafis Shafizadeh, James P. Grenert, Vaibhav Sahai, Sanjay Kakar</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.002</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-30</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-30</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003736/abstract?rss=yes"><title>Fibrocytes are involved in the pathogenesis of human chronic kidney disease - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003736/abstract?rss=yes</link><description>Summary: The presence of chronic kidney disease in humans is associated with a risk of kidney function loss as well as the development of cardiovascular disease. Fibrocytes have been shown to contribute to organ fibrosis. In this study, the presence of fibrocytes was investigated immunohistochemically in kidney biopsy specimens from 100 patients with chronic kidney disease. In addition, 6 patients with thin basement membrane disease were studied as a disease control. In patients with chronic kidney disease, the infiltration of fibrocytes was observed mainly in the interstitium. The number of interstitial fibrocytes in patients with chronic kidney disease was higher than that in patients with thin basement membrane disease. The number of infiltrated fibrocytes in the interstitium correlated well with the severity of tubulointerstitial lesions, such as interstitial fibrosis, in patients with chronic kidney disease. In addition, there were significant correlations between the number of interstitial fibrocytes and the number of CD68-positive macrophages in the interstitium as well as urinary monocyte chemoattractant protein-1/CCL2 levels. In particular, there was an inverse correlation between the number of interstitial fibrocytes and kidney function at the time of biopsy. Finally, the numbers of interstitial fibrocytes and macrophages as well as urinary CCL2 levels were significantly decreased during convalescence induced by glucocorticoid therapy. These results suggest that fibrocytes may be involved in the pathogenesis of chronic kidney disease through the interaction with macrophages as well as CCL2.</description><dc:title>Fibrocytes are involved in the pathogenesis of human chronic kidney disease - Corrected Proof</dc:title><dc:creator>Norihiko Sakai, Kengo Furuichi, Yasuyuki Shinozaki, Hiroyuki Yamauchi, Tadashi Toyama, Shinji Kitajima, Toshiya Okumura, Satoshi Kokubo, Motoo Kobayashi, Kazuya Takasawa, Shin-ichi Takeda, Mitsuhiro Yoshimura, Shuichi Kaneko, Takashi Wada</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.008</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-30</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-30</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003918/abstract?rss=yes"><title>Mast cell phenotypes and microvessels in non–small cell lung cancer and its prognostic significance - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003918/abstract?rss=yes</link><description>Summary: The impact of interstitial inflammatory cells, such as mast cells, and angiogenesis on the prognosis of cancer patients has been reported in many solid tumors, although there is disagreement about their role. We undertook a retrospective study with tissue samples from 65 patients with stage I and II non–small cell lung cancer to assess the clinical pathologic role and prognostic significance of mast cells. Mast cell phenotypes were identified by immunohistochemistry for tryptase and chymase. In addition, we identified microvessels using the endothelial marker CD34. Mast cell and microvessel density was quantified by assessing immunopositive cells in the intratumoral and peritumoral zones of tumor specimens. Both mast cell and microvessel density was higher in the peritumoral zone than the intratumoral zone (P ≤ .05). A positive correlation between mast cell (tryptase-chymase phenotype) and microvessel densities was observed in the intratumoral zone (P ≤ .05), supporting the involvement of mast cells in the angiogenic process. Regarding survival, a subset of stage I patients had a worse prognosis at five years when low mast cell (tryptase-chymase phenotype) density was found in the peritumoral zone (median survival in months [range]: 27 [1-60] versus 46 [1-60]). Multivariate Cox analysis indicated that this parameter may be an independent prognostic factor (P ≤ .05) useful for selecting candidates for earlier treatment.</description><dc:title>Mast cell phenotypes and microvessels in non–small cell lung cancer and its prognostic significance - Corrected Proof</dc:title><dc:creator>María José Carlini, Mercedes Corina Liliana Dalurzo, José María Lastiri, David Eduardo Smith, Bartolomé Carlos Vasallo, Lydia Inés Puricelli, Lilia Susana Lauría de Cidre</dc:creator><dc:identifier>10.1016/j.humpath.2009.04.029</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-30</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-30</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003311/abstract?rss=yes"><title>Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003311/abstract?rss=yes</link><description>Summary: This study reports the presence of surprisingly frequent and often severe interstitial fibrosis in cigarette smokers with no clinical evidence of interstitial lung disease. Twenty-three lobectomy specimens excised for neoplasms, including 20 from smokers, were extensively sampled, and examined semi-quantitatively for interstitial fibrosis, fibroblast foci, peribronchiolar metaplasia, honey-comb change, emphysema, and respiratory bronchiolitis. Interstitial fibrosis involving greater than 25% of slides was identified in 12 of 20 smokers (60%), but in none of the three never-smokers. Three cases were classified as specific forms of interstitial lung disease, including one each of usual interstitial pneumonia, Langerhans cell histiocytosis, and asbestosis. The remaining 9 cases did not fit with a named interstitial lung disease and were considered to represent examples of smoking-related interstitial fibrosis. This lesion was characterized by varying degrees of alveolar septal widening by collagen deposition along with emphysema and respiratory bronchiolitis. The fibrosis occurred both in subpleural and in deeper parenchyma. It surrounded enlarged airspaces of emphysema, but it also involved non-emphysematous parenchyma. Clinical progression was not documented in any case, although follow-up was short. These observations highlight the spectrum of unexpected fibrosis that is frequently encountered in lobectomy specimens from cigarette smokers. Additional investigation will be required to determine the clinical significance of smoking-related interstitial fibrosis and its relationship, if any, to other smoking-related diseases. It is important, however, that smoking-related interstitial fibrosis be distinguished from specific forms of fibrosing lung disease that may be associated with poor prognoses, especially usual interstitial pneumonia.</description><dc:title>Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens - Corrected Proof</dc:title><dc:creator>Anna-Luise A. Katzenstein, Sanjay Mukhopadhyay, Conrado Zanardi, Elizabeth Dexter</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.003</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-14</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-14</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709002962/abstract?rss=yes"><title>Lymphatic and blood vessels in scleroderma skin, a morphometric analysis - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709002962/abstract?rss=yes</link><description>Summary: Vascular involvement is frequent in systemic sclerosis, but the role of the lymphatic vasculature is poorly known. Our aim was to evaluate lymphatic vessels in systemic sclerosis skin lesions. We studied skin forearm biopsies of 9 patients with systemic sclerosis and 7 age-matched controls. Lymphatic vessels were labeled with the monoclonal antibody D2-40 and blood vessels with a polyclonal antibody to von Willebrand Factor. All blood and lymphatic vessels present in each section were counted and total area, inner luminal area, and shape factors were measured. The number of blood and lymphatic vessels in papillary dermis was greater and their diameter lower than in reticular dermis both in systemic sclerosis and controls. In the reticular dermis, the number of lymphatic vessels was markedly reduced in systemic sclerosis (4.9 ± 1.1 μm−2 versus 8.9 ± 1.2 μm−2 P = .03), and a similar trend was observed in papillary dermis (8.4 ± 3.7 μm−2 versus 8.1 ± 5.3 μm−2). Interestingly, the number of periglandular lymphatics in systemic sclerosis was not different from controls. The inner luminal area (possibly indicating compensatory dilation) of lymphatic vessels, particularly the periglandular ones, was greater in systemic sclerosis than in controls. No differences were observed in the number of blood vessels, but the percentage of blood vessel profiles (without lumen) was significantly less in systemic sclerosis both in papillary and in reticular dermis. In conclusion, our data show that skin lesions in systemic sclerosis are characterized by a selective rarefaction of lymphatic vasculature that spares periglandular vessels and that might have a pathogenic role in the evolution and in the clinical manifestations of the disease.</description><dc:title>Lymphatic and blood vessels in scleroderma skin, a morphometric analysis - Corrected Proof</dc:title><dc:creator>Antonella Rossi, Francesca Sozio, Piersante Sestini, Elisabetta A. Renzoni, Korsa Khan, Christopher P. Denton, David J. Abraham, Elisabetta Weber</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.009</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709002998/abstract?rss=yes"><title>Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709002998/abstract?rss=yes</link><description>Summary: Angiogenesis is required for progression and metastasis of melanoma. Analysis of angiogenic molecules in benign and malignant tissues may allow identification of markers useful for prediction of sensitivity to antiangiogenic agents. We hypothesized that differential expression of vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, VEGF-R2, and VEGF-R3 would be higher in melanomas than nevi and higher in advanced melanoma. Using automated quantitative analysis, we quantified VEGF, -R1, -R2 and -R3 expression in melanoma tissue microarrays composed of 540 nevi and 468 melanoma specimens (198 primaries, 270 metastases). VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 expression was significantly higher in melanomas than nevi by unpaired t tests (P &lt; .0001). VEGF-R2 expression was higher in metastatic specimens (P &lt; .0001), but VEGF-R3 expression was higher in primaries (P &lt; .0001). VEGF was coexpressed with all 3 receptors when assessed by Spearman's rank correlation. VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 expression is higher in melanomas than nevi. Higher expression of VEGF-R2 was found in metastases versus primaries, supporting the idea that selection for an angiogenic phenotype in metastatic melanoma is conferred via up-regulation of VEGF-R2. However, higher expression of VEGF-R3 was seen on primary lesions, potentially implicating this receptor in initiation of lymphatic tumor spread. Clinical trials using antiangiogenic agents in melanoma should include correlative assays of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 as biomarkers of response to therapy, preferably using quantitative methods such as automated quantitative analysis. Such assessments could assist with evaluation of these molecules as therapeutic targets in melanoma, ultimately facilitating improved selection of patients for treatment.</description><dc:title>Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays - Corrected Proof</dc:title><dc:creator>Janice M. Mehnert, Mary M. McCarthy, Lucia Jilaveanu, Keith T. Flaherty, Saadia Aziz, Robert L. Camp, David L. Rimm, Harriet M. Kluger</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.016</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003219/abstract?rss=yes"><title>Post-mortem pathologic and genetic studies in “dead in bed syndrome” cases in type 1 diabetes mellitus - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003219/abstract?rss=yes</link><description>Summary: Dead in bed syndrome is a poorly understood cause of sudden death in young people with type 1 diabetes. The underlying cause remains unknown. One possible explanation may involve prolongation of the QT interval followed by a terminal malignant arrhythmia. Risk factors associated with QT interval prolongation include hypoglycemia and cardiac autonomic neuropathy. We sought to identify myocardial cellular changes and genetic influences that may contribute to the pathogenesis of dead in bed syndrome. Post-mortem reports between 1994 and 2006 from the 2 largest Departments of Forensic Medicine in Australia were reviewed for dead in bed syndrome cases. Post-mortem heart sections were immunohistochemically stained for collagen types I and III and connective tissue growth factor (CTGF). Genomic DNA was prepared from post-mortem samples, and genetic analysis was performed in the SCN5A, G6PC, PHOX2B, and CTGF genes. Twenty-two dead in bed syndrome cases were identified and staining of heart sections for collagen I and III, and CTGF showed no differences between dead in bed syndrome cases and controls. Genetic screening of SCN5A revealed 3 silent polymorphisms A29A, E1061E, and D1819D and 1 protein-changing variant H558R. No genetic variants were found in G6PC, PHOX2B, and CTGF, and dead in bed syndrome cases were not associated with the G-945C CTGF promoter polymorphism. In conclusion, this study is the first to investigate potential pathogenic mechanisms underlying the dead in bed syndrome in type 1 diabetes with the results substantially adding to knowledge of this condition. Understanding the causes and triggers of dead in bed syndrome will be critical in facilitating the identification of patients with type 1 diabetes at highest risk of developing sudden death.</description><dc:title>Post-mortem pathologic and genetic studies in “dead in bed syndrome” cases in type 1 diabetes mellitus - Corrected Proof</dc:title><dc:creator>Emily Tu, Richard D. Bagnall, Johan Duflou, Matthew Lynch, Stephen M. Twigg, Christopher Semsarian</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.020</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS004681770900330X/abstract?rss=yes"><title>Case report: focal nesidioblastosis (“nesidioblastoma”) in an adult - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS004681770900330X/abstract?rss=yes</link><description>Summary: Adult nesidioblastosis is an uncommon cause of hyperinsulinemic hypoglycemia characterized by diffuse islet hyperplasia with β-cell hypertrophy and atypia. The cause of nesidioblastosis in adults is unclear but may be different from nesidioblastosis in infants. In contrast to infants, a focal form of adult nesidioblastosis (ie, “nesidioblastoma”) has not been documented, although proposed. We report a 44-year-old man with symptomatic hypoglycemia and localized nesidioblastosis treated with surgical enucleation resulting in normalization of blood glucose. Postoperative euglycemia has persisted in this patient to date (4 months at the time of manuscript submission).</description><dc:title>Case report: focal nesidioblastosis (“nesidioblastoma”) in an adult - Corrected Proof</dc:title><dc:creator>Michele K. McElroy, Andrew M. Lowy, Noel Weidner</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.002</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>CASE STUDY</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003323/abstract?rss=yes"><title>Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003323/abstract?rss=yes</link><description>Summary: Beclin 1 and LC3 autophagic genes are altered in several human cancer types. This study was designed to assess the expression of Beclin 1 and LC3 in cutaneous melanocytic lesions, in which they have not yet been investigated. In melanoma, we correlated their expression with conventional histopathologic prognostic factors. In 149 lesions, including benign nevi, dysplastic nevi, radial growth phase melanomas, vertical growth phase melanomas, and melanoma metastases, proteins were evaluated by immunohistochemistry, and, in representative cases of benign nevi, vertical growth phase melanomas and melanoma metastases were evaluated by Western blotting. In most lesions, messenger RNA level was also assessed by real-time reverse transcriptase polymerase chain reaction. Both genes were expressed in all the investigated conditions. Beclin 1 cytoplasmic protein and messenger RNA, as well as LC3 messenger RNA, significantly decreased with tumor progression (P &lt; .05). The percentage of cases with high cytoplasmic expression of beclin 1 from 100% in benign nevi declined to 86.4% in dysplastic nevi, 54.5% in radial growth phase melanomas, 54.3% in vertical growth phase melanomas, and 26.7% in melanoma metastases. The lowest expression of LC3 II protein was observed in melanoma metastases (53.3% of cases) (P &lt; .05); LC3 II protein overexpression was, however, found in several nonbenign lesions, with the highest percentage (45.5%) in radial growth phase melanomas. LC3 II protein expression was inversely correlated to thickness, ulceration, and mitotic rate. In a multivariate analysis, messenger RNAs for both genes discriminated between nonmalignant (benign and dysplastic nevi) and malignant (radial, vertical growth phase melanomas, and melanoma metastases) lesions. Our results, therefore, indicate that beclin 1 and LC3 II autophagic gene expression is altered also in melanocytic neoplasms.</description><dc:title>Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions - Corrected Proof</dc:title><dc:creator>Clelia Miracco, Gabriele Cevenini, Alessandro Franchi, Pietro Luzi, Elena Cosci, Vasileios Mourmouras, Irene Monciatti, Susanna Mannucci, Maurizio Biagioli, Marzia Toscano, Daniele Moretti, Roberto Lio, Daniela Massi</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.004</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003347/abstract?rss=yes"><title>Flat epithelial atypia is a common subtype of B3 breast lesions and associated with noninvasive cancer but not with invasive cancer in final excision histology - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003347/abstract?rss=yes</link><description>Summary: The biological behavior and the optimal management of benign breast lesions with uncertain malignant potential, the so-called B3 lesions, found in breast needle core biopsies is still under debate. We addressed this study to compare histologic findings in B3 needle core biopsies with final excision specimens to determine associated rates of malignancy. Consecutive needle core biopsies were performed in a 3-year period (January 1, 2006-December 31, 2008). Biopsies were image-guided (31 by ultrasound, 85 stereotactic vacuum-assisted, 6 unknown) for evaluation of breast abnormalities. We reviewed 122 needle core biopsies with B3 lesions of 91 symptomatic patients and 31 screen-detected women and compared the B3 histologic subtypes with the final excision histology. A total of 1845 needle core biopsies were performed and B3 lesions comprised 6.6% of all B categories. The most common histologic subtype in biopsies was flat epithelia atypia in 35.2%, followed by papillary lesions in 21% and atypical ductal hyperplasia in 20%. Reports on excision specimens were available in 66% (81 patients). Final excision histology was benign in 73 (90.2%) and malignant in 8 (9.8%) patients (2 invasive cancer, 6 ductal carcinoma in situ). Of all B3 subtypes, atypical ductal hyperplasia and flat epithelial atypia were associated with malignancy, whereas only atypical ductal hyperplasia was accompanied by invasive cancer. Of all lesions, flat epithelial atypia was most frequently found in excision specimens (18%). In our study, flat epithelial atypia and atypical ductal hyperplasia are common lesions of the B3 category in needle core biopsies of the breast. Both lesions are associated with malignancy, whereas only atypical ductal hyperplasia was related to invasive cancer. We conclude that an excision biopsy after diagnosis of flat epithelial atypia is recommended depending on clinical and radiologic findings.</description><dc:title>Flat epithelial atypia is a common subtype of B3 breast lesions and associated with noninvasive cancer but not with invasive cancer in final excision histology - Corrected Proof</dc:title><dc:creator>Aurelia Noske, Stefan Pahl, Eva Fallenberg, Christiane Richter-Ehrenstein, Ann-Christin Buckendahl, Wilko Weichert, Achim Schneider, Manfred Dietel, Carsten Denkert</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.005</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003359/abstract?rss=yes"><title>Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003359/abstract?rss=yes</link><description>Summary: In addition to Rb1, the causative genes involved in the tumorigenesis and progression of retinoblastomas remain to be elucidated. High-mobility group A1 and high-mobility group A2 proteins are expressed at high levels in various benign and malignant tumors and are associated with expressions of malignant phenotypes and poor prognoses. Reduction in let-7 expression levels was detected in cancers; it may be related to high-mobility group A1 and high-mobility group A2 overexpressions. Little is known about the correlations among high-mobility group A1, high-mobility group A2, and let-7 expression and clinicopathologic features of retinoblastoma. In our study, the expressions of high-mobility group A1 and high-mobility group A2 were studied in 44 retinoblastomas by immunohistochemical analysis. Semiquantitative reverse transcription-polymerase chain reaction was used to assay the let-7 expression levels in 28 nontumor retina and 44 tumor samples. Nuclear immunostaining of high-mobility group A1 and high-mobility group A2 was frequently observed in retinoblastomas (68% and 75%, respectively). Expression levels of both high-mobility group A1 and high-mobility group A2 were significantly higher in poorly differentiated retinoblastomas than in well-differentiated retinoblastomas (P &lt; .05 and P &lt; .0001, respectively). In addition, overexpressions of high-mobility group A1 and high-mobility group A2 were more frequently detected in poorly differentiated tumors than in well-differentiated tumors (P &lt; .01 and P = .0001, respectively). High-mobility group A2 expression levels were significantly higher in invasive tumors than in noninvasive tumors (P &lt; .05). In addition, the MIB-1 labeling index was higher in poorly differentiated tumors than in well-differentiated tumors (P &lt; .0001). Our study revealed that high-mobility group A1 and high-mobility group A2 expressions correlated with the MIB-1 labeling index (R = 0.327, P = .029; R = 0.602, P &lt; .0001; respectively). The let-7 was expressed in high levels in all 28 nontumor retina samples. However, reduced expression levels of let-7 were observed in 17 (39%) tumors. A potentially inverse correlation exists between the expression levels of let-7 and high-mobility group A1 (r = −0.247, P = .105). In addition, a significantly inverse association was detected between let-7 and high-mobility group A2 and MIB-1 labeling index (r = −0.31, P = .04; r = −0.392, P = .007, respectively). Our findings imply that the overexpressions of high-mobility group A1, high-mobility group A2, and down-regulation of let-7 may be associated with tumorigenesis and progression of retinoblastomas.</description><dc:title>Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas - Corrected Proof</dc:title><dc:creator>Guoying Mu, Han Liu, Fang Zhou, Xiaoyi Xu, Hua Jiang, Yan Wang, Yi Qu</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.022</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003360/abstract?rss=yes"><title>Characterization of enteroglial cells and denervation process in chagasic patients with and without megaesophagus - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003360/abstract?rss=yes</link><description>Summary: Chagas disease is caused by infestation with the parasite Trypanosoma cruzi, and some patients who are serologically positive develop chronic megaesophagus, whereas others are symptom-free. Gastrointestinal form of Chagas disease involves an inflammatory invasion of the enteric plexuses and degeneration of enteric neurons and previous works related that enteroglial cells would be involved in enteric inflammatory responses. Because of this, the aims of this study were to determine the relation of enteroglial cells with the denervation process in chagasic patients with and without megaesophagus and seronegative individuals. Our results indicated that the innervation of the esophageal muscle was substantially reduced in patients with megaesophagus, but asymptomatic seropositive subjects were not different to seronegative controls. Besides, patients with megaesophagus had significant decreased of enteroglial cells labeled with S-100 and glial fibrillary acidic protein, whereas patients without megaesophagus presented an increased of both labels. We believe that enteroglial cells would operate a mechanism of defense in the enteric nervous system against the Trypanosoma cruzi infection, which could prevent the organ denervation and preserve the esophagus function.</description><dc:title>Characterization of enteroglial cells and denervation process in chagasic patients with and without megaesophagus - Corrected Proof</dc:title><dc:creator>Rodolfo Duarte Nascimento, André de Souza Lisboa, Ricardo Toshio Fujiwara, Michelle Aparecida Ribeiro de Freitas, Sheila Jorge Adad, Rodrigo Correa Oliveira, Débora d'Ávila Reis, Alexandre Barcelos Morais da Silveira</dc:creator><dc:identifier>10.1016/j.humpath.2009.05.018</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003530/abstract?rss=yes"><title>Expression of p16 in benign and malignant cystic squamous lesions of the neck - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003530/abstract?rss=yes</link><description>Summary: Metastatic cystic squamous cell carcinomas of the neck often harbor human papillomavirus 16 and, in turn, overexpress p16. P16 immunohistochemistry could be useful in the evaluation of patients who present with cystic squamous lesions of the neck, particularly when the distinction between a benign lymphoepithelial cyst and a metastatic squamous cell carcinoma cannot be easily resolved on clinical or pathologic grounds. Implementation of this strategy, however, awaits a description of p16 expression in benign lymphoepithelial cysts. The purpose of this study was to evaluate p16 staining in cystic squamous lesions of the neck with an emphasis on benign lymphoepithelial cysts. P16 immunohistochemistry was performed on tissue sections and fine needle aspirates of benign (n = 49) and malignant (n = 16) squamous lesions of the neck. P16-positive cases were further evaluated by human papillomavirus 16 in situ hybridization. P16 staining was seen in the tissue sections of 16 of 37 (43%) benign lymphoepithelial cysts. P16 staining tended to localize to regions of the squamous epithelium penetrated by interdigitating lymphocytes. In the aspirates, p16 staining was noted in 5 of 12 (42%) benign lymphoepithelial cysts and in 3 of 16 (19%) cystic squamous cell carcinomas. Human papillomavirus 16 was detected in the 3 p16-positive cystic squamous cell carcinomas but in none of the p16-positive benign lymphoepithelial cysts. P16 overexpression is not always linked to high-risk human papillomavirus integration, but may be intrinsic to the reticulated epithelium that lines benign lymphoepithelial cysts. This observation limits the role of p16 staining as a surrogate marker of human papillomavirus 16 infection and as a diagnostic tool in separating benign from malignant cystic squamous lesions of the neck.</description><dc:title>Expression of p16 in benign and malignant cystic squamous lesions of the neck - Corrected Proof</dc:title><dc:creator>Dengfeng Cao, Shahnaz Begum, Syed Z. Ali, William H. Westra</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.006</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003542/abstract?rss=yes"><title>Defining the borders of splenic marginal zone lymphoma: a multiparameter study - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003542/abstract?rss=yes</link><description>Summary: Classic splenic marginal zone lymphomas are CD5−, CD10−, CD23−, CD43−, and usually IgD+ with biphasic white pulp nodules. However, the 2008 World Health Organization classification accepts splenic marginal zone lymphomas with monophasic marginal zone-like white pulp nodules and recognizes a group of unclassifiable splenic small B-cell lymphomas. To explore the relationship of classic splenic marginal zone lymphomas to these other less well-defined splenic lymphomas, a multiparameter study of 47 splenic marginal zone lymphomas and unclassifiable splenic small B-cell lymphomas was performed. Seventeen of 31 splenic marginal zone lymphomas were biphasic, and 14 were monophasic (90%-100% marginal zone-like white pulp nodules). Sixteen cases were unclassifiable splenic small B-cell lymphomas, most lacking a marginal zone-type component. There were many clinical similarities between the 3 groups, including similar survivals. Monophasic and unclassifiable cases were less likely to have a typical splenic marginal zone lymphoma phenotype (28.6%, 23.1%) compared with biphasic cases (86.7%), usually because of IgD negativity (P &lt; .003). Thirty-four of 42 (81%) cases had cytogenetic abnormalities by fluorescence in situ hybridization; and 17 of 20 (85%), by classical cytogenetics. The most frequent fluorescence in situ hybridization abnormalities among the splenic marginal zone lymphomas were del(7)(q31) (26%), +12 (25%), and +3q27 (27%); and among the unclassifiable cases, +12 (50%) and +3q27 (36%). Five of 6 unclassifiable cases with exclusively small non-marginal zone-like lymphocytes involving both white and red pulp had +12 compared with 9 of 34 other cases (P &lt; .02). CDK6 (2 cases) and BCL3 (1 case) rearrangements were only seen in the unclassifiable group. These results support including both biphasic and monophasic cases as splenic marginal zone lymphomas, but suggest that the lack of a non-marginal zone-like population in the monophasic group is associated with some biologic differences. They also demonstrate a relatively large proportion of unclassifiable cases, including a group with frequent +12.</description><dc:title>Defining the borders of splenic marginal zone lymphoma: a multiparameter study - Corrected Proof</dc:title><dc:creator>Scott D. Dufresne, Raymond E. Felgar, Rachel L. Sargent, Urvashi Surti, Susanne M. Gollin, Ellen D. McPhail, James R. Cook, Steven H. Swerdlow</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.007</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003554/abstract?rss=yes"><title>Large cell calcifying Sertoli cell tumor: a clinicopathologic study of 1 malignant and 3 benign tumors using histomorphology, immunohistochemistry, ultrastructure, comparative genomic hybridization, and polymerase chain reaction analysis of the PRKAR1A gene - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003554/abstract?rss=yes</link><description>Summary: Four cases of large cell calcifying Sertoli cell tumor, 3 benign and 1 malignant, with no clinical signs of Carney complex or Peutz-Jeghers syndrome are reported with results of histologic, immunohistochemical, ultrastructural, and comparative genomic hybridization studies. Analysis of PRKAR1A gene was performed on 2 cases. The age range of the patients was 19 to 54 years. The patient with a malignant large cell calcifying Sertoli cell tumor died of disease 4 years after surgery. Patients with benign tumors have had an uneventful follow-up for 1 and 3 years. All tumors were well circumscribed, unencapsulated, and composed of solid sheets, irregular cords, tubular structures, and nests in a fibrous and/or myxoid stroma with cellular atypia in the malignant case. All tumors showed diffuse immunoreactivity for inhibin, vimentin, calretinin, and S100 protein. Focal positivity for cytokeratin (AE1/AE3) was noticed in 1 case. Tumors were negative for CAM 5.2, Mic-2, Melan-A laminin, placental alkaline phosphatase, and α-fetoprotein. The proliferation index was 5% and 10% for 2 of the benign tumors and 30% for the malignant tumor. Comparative genomic hybridization was performed in 2 cases. There was no evidence of any major chromosomal changes. In one case, no PRKAR1A gene mutation was found. In the other case, a heterozygous shift mutation c.65_84dup was found, despite the absence of other clinical signs of Carney complex or Peutz-Jeghers syndrome. Although the combination of large cell calcifying Sertoli cell tumor and PRKAR1A mutation fulfills the criteria for establishing a diagnosis of Carney complex, the clinical relevance of finding a PRKAR1A gene mutation in a patient without any clinical signs of Carney complex or Peutz-Jeghers syndrome remains to be established.</description><dc:title>Large cell calcifying Sertoli cell tumor: a clinicopathologic study of 1 malignant and 3 benign tumors using histomorphology, immunohistochemistry, ultrastructure, comparative genomic hybridization, and polymerase chain reaction analysis of the PRKAR1A gene - Corrected Proof</dc:title><dc:creator>Fredrik Petersson, Stela Bulimbasic, Radek Sima, Michal Michal, Milan Hora, Hugo Dominguez Malagon, Josef Matoska, Ondrej Hes</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.008</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003578/abstract?rss=yes"><title>Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003578/abstract?rss=yes</link><description>Summary: Tthyroid transcription factor 1 is a marker of lung and thyroid carcinomas, but thyroid transcription factor 1 immunoreactivity is seen in other malignancies. We examined the incidence of thyroid transcription factor 1 expression in gynecologic tumors in Japanese patients, and we further evaluated the presence of epidermal growth factor receptor mutations in thyroid transcription factor 1–positive gynecologic malignancies. A total of 186 patient samples collected at our hospitals between 1991 and 2006 were analyzed, and these specimens consisted of 83 ovarian carcinomas, 55 endometrioid endometrial adenocarcinomas of the uterus, 28 cervical adenocarcinomas of the uterus, and 20 leiomyosarcomas of the uterus. Thyroid transcription factor 1 expression was assessed by immunohistochemistry. The presence of epidermal growth factor receptor mutations was investigated by polymerase chain reaction analyses. Thyroid transcription factor 1 was detected in the nuclei of 11 ovarian carcinomas (13%) and 5 endometrioid adenocarcinomas (10%) of the uterus. In patients with ovarian carcinoma, thyroid transcription factor 1 staining was associated with significantly improved progression-free (P = .017) and overall survival (P = .017) using univariate analysis. Multivariate analysis identified thyroid transcription factor 1 expression as an independent prognostic factor for ovarian cancer (P = .0467). No epidermal growth factor receptor mutations were found in our study. Thyroid transcription factor 1 is expressed with relatively low frequencies in gynecologic malignancies, but thyroid transcription factor 1 expression confers a better prognosis in patients with ovarian cancer. No epidermal growth factor receptor mutations were found in the thyroid transcription factor 1–positive gynecologic malignancies, and we were unable to establish a relationship between epidermal growth factor receptor mutations and thyroid transcription factor 1 immunopositivity, as was previously shown for lung cancer.</description><dc:title>Thyroid transcription factor 1 expression in ovarian carcinomas is an independent prognostic factor - Corrected Proof</dc:title><dc:creator>Sawako Fujiwara, Akihiro Nawa, Toru Nakanishi, Yoshie Shimoyama, Hiroaki Kajiyama, Kiyosumi Shibata, Kazuhiko Ino, Shigeo Nakamura, Fumitaka Kikkawa, Yasushi Yatabe</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.010</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003591/abstract?rss=yes"><title>If not, why not? Reasons why Canadian postgraduate trainees chose—or did not choose—to become pathologists - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003591/abstract?rss=yes</link><description>Summary: Pathology has been frequently identified in the literature as an unpopular choice for medical students. For many years, there have been predictions that this unpopularity would lead to inadequate pathologist numbers, which would in turn contribute to poor quality patient care. In Canada, the predicted crisis has become a reality: after a high-profile failure of laboratory quality, a public inquiry reported that poor pathology recruitment was partially responsible and recommended that medical schools take steps to make pathology more attractive to medical students. There are several published studies into pathology recruitment, but none has asked nonpathology residents why they did not choose pathology. This study uses qualitative techniques to investigate why pathology residents chose to specialize in pathology and why clinical residents rejected a pathology career. Pathology residents across Canada were surveyed, as were clinical (nonpathology) residents in every residency training program at the University of British Columbia in Vancouver, Canada. Pathology residents overwhelmingly cited various attractive features of pathology practice, including its academic nature, the opportunity to explore basic pathogenesis, and its interesting and varied daily work. Most clinical residents rejected pathology because they preferred direct patient contact; however, a sizable minority blamed insufficient or inadequate medical school experiences in pathology. Clinical residents also cited several misconceptions and stereotypes about pathology, including misunderstandings about the role of pathologists and the nature of pathology practice. The reasons why clinical residents rejected pathology careers may provide guidance in improving pathology recruitment of medical students.</description><dc:title>If not, why not? Reasons why Canadian postgraduate trainees chose—or did not choose—to become pathologists - Corrected Proof</dc:title><dc:creator>Jason C. Ford</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.012</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003608/abstract?rss=yes"><title>Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003608/abstract?rss=yes</link><description>Summary: Breast cancer cells with the CD44+/CD24− phenotype have been associated with stem cell properties. To analyze effects of cytotoxic chemotherapy on these cells, we examined a series of 50 breast carcinomas before and after neoadjuvant chemotherapy with epirubicin/cyclophosphamide using double immunofluorescence. Before treatment, an average of 4.4% of the tumor cells displayed a CD44+/CD24− phenotype. However, after chemotherapy, the frequency of CD44+/CD24− cells dropped to 2% (P = .008). To test this unexpected finding, we analyzed a second collective of 16 patients that preoperatively had received either 4 cycles of doxorubicin/pemetrexed, followed by 4 cycles of docetaxel or 4 cycles of doxorubicin/cyclophosphamide, followed by 4 cycles of docetaxel with similar results (8.7% CD44+/CD24− cells on average before and 1.1% after chemotherapy). In addition, no association was observed between the frequency of CD44+/CD24− cells and the response to chemotherapy or patient survival. However, patients with tumors containing high numbers of CD44+/CD24− cells more frequently developed bone metastases in the course of disease. In conclusion, our findings challenge the proposed role of CD44+/CD24− cells as cancer stem cells in tumor resistance to chemotherapy as they apparently are not selected by conventional cytotoxic agents.</description><dc:title>Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy - Corrected Proof</dc:title><dc:creator>Sebastian Aulmann, Nina Waldburger, Roland Penzel, Mindaugas Andrulis, Peter Schirmacher, Hans Peter Sinn</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.023</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS004681770900361X/abstract?rss=yes"><title>Interstitial inflammation in Alport syndrome - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS004681770900361X/abstract?rss=yes</link><description>Summary: The Alport syndrome is a hereditary glomerular disease linked to structural abnormalities of collagen IV. In a mouse model of Alport syndrome, the interstitial lymphocyte influx was important for disease progression. CXCR3 is a chemokine receptor involved in lymphocyte recruitment to the kidney. We hypothesized that CXCR3-positive T cells might be involved in human Alport syndrome. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded biopsies from 17 patients with Alport syndrome, 10 with immunoglobulin A (IgA) nephropathy, and 11 healthy donor kidneys. We investigated the expression of the α5 chain of collagen IV to confirm the morphologic diagnosis, the chemokine receptor CXCR3 and CD3-positive T cells. Alport syndrome biopsies demonstrated a complete loss of the α5 chain of collagen IV from the glomerular basement membrane and the morphologic features consistent with Alport syndrome on electron microscopy. A prominent number of CXCR3-positive cells were found in the tubulointerstitium. Most of the CXCR3-positive cells were CD3-positive T cells, demonstrated by double-labeling in selected biopsies. The number of CXCR3-positive cells in kidneys with Alport syndrome correlated with serum creatinine (P &lt; .05) and with morphologic features of a progressive disease (eg, interstitial fibrosis, glomerulosclerosis, and tubular atrophy). The severity of interstitial CXCR3-positive cell influx was similar in Alport syndrome as compared to immunoglobulin A nephropathy. The noninflammatory glomerular lesion of Alport syndrome is associated with prominent interstitial accumulation of CD3- and CXCR3-positive lymphocytes. The degree of infiltration correlated with renal function. We speculate that targeting T lymphocytes, for example, by CXCR3 blocking agents, might be a novel approach to inhibit disease progression in patients with Alport syndrome.</description><dc:title>Interstitial inflammation in Alport syndrome - Corrected Proof</dc:title><dc:creator>Jan Jedlicka, Afschin Soleiman, Dan Draganovici, Jana Mandelbaum, Urs Ziegler, Heinz Regele, Rudolf P. Wüthrich, Oliver Gross, Hans-Joachim Anders, Stephan Segerer</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.024</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003694/abstract?rss=yes"><title>IMP3 expression is correlated with histologic grade of lung adenocarcinoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003694/abstract?rss=yes</link><description>Summary: Insulin-like growth factor II mRNA binding protein 3 is an oncofetal protein that is expressed in multiple malignancies. This study aimed to determine the correlation of insulin-like growth factor II mRNA binding protein 3 expression with histologic grade of lung adenocarcinoma. Eighty-nine cases, including 11 atypical adenomatous hyperplasias, 10 pure bronchioloalveolar carcinomas, 36 well-differentiated adenocarcinomas and 41 moderately or poorly differentiated adenocarcinomas, were immunohistochemically studied using a monoclonal antibody against insulin-like growth factor II mRNA binding protein 3. Twenty-nine (70.7%) of 41 moderately to poorly differentiated adenocarcinomas were positive for insulin-like growth factor II mRNA binding protein 3, with 26 (89.7%) tumors demonstrating either a strong staining or staining in greater than 30% of tumor cells. Four (40.0%) of 10 bronchioloalveolar carcinomas and 13 (36.1%) of 36 well-differentiated adenocarcinomas exhibited insulin-like growth factor II mRNA binding protein 3 positivity with a variable degree and percentage of tumor cells staining. When bronchioloalveolar carcinomas were present in a pure form or as a component of adenocarcinomas, positive insulin-like growth factor II mRNA binding protein 3 staining was always patchy, with less than 20% of tumor cells stained. Overall, the frequency of positive insulin-like growth factor II mRNA binding protein 3 staining was lower in bronchioloalveolar carcinomas and well-differentiated adenocarcinomas compared to moderately/poorly differentiated adenocarcinomas (P &lt; .01). No insulin-like growth factor II mRNA binding protein 3 signal was detected in any case of atypical adenomatous hyperplasia. These findings show that insulin-like growth factor II mRNA binding protein 3 is strongly and diffusely expressed in a large proportion of moderately/poorly differentiated lung adenocarcinomas, in particular in the solid component of mixed subtype adenocarcinomas, less frequently expressed in well-differentiated adenocarcinomas and bronchioloalveolar carcinomas, and negative in atypical adenomatous hyperplasias. The higher frequency of expression in moderately/poorly differentiated adenocarcinomas suggests that insulin-like growth factor II mRNA binding protein 3 expression may be associated with an aggressive biological behavior.</description><dc:title>IMP3 expression is correlated with histologic grade of lung adenocarcinoma - Corrected Proof</dc:title><dc:creator>Jennifer J. Findeis-Hosey, Qi Yang, Betsy O. Spaulding, Hanlin L. Wang, Haodong Xu</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.004</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003700/abstract?rss=yes"><title>Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003700/abstract?rss=yes</link><description>Summary: In this article, we supplement the few published articles by describing the clinical and pathologic features of pleomorphic and dedifferentiated leiomyosarcoma from 41 patients (27 women and 14 men) with an age range of 25 to 75 years (mean, 56.5 years), representing the largest cohort reported to date. The typical leiomyosarcoma component accounted for &lt;5% to 60% (mean, 15%) of the tumor. The pleomorphic sarcoma component was composed of polygonal cells in 57% of cases, spindle cells in 21%, a combination of polygonal, epithelioid, rhabdoid, and/or spindle cells in 18%, and predominantly epithelioid cells in 3%. The classical leiomyosarcoma component was positive for at least one myogenic immunohistochemical marker in 29 tumors tested; smooth muscle actin in 100% (27/27), calponin in 90% (9/10), muscle-specific actin in 90% (10/11), desmin in 86% (23/27), smooth muscle myosin heavy chain (SMMS-1) in 67% (4/6), and caldesmon in 57% (4/7). The pleomorphic sarcoma component was reactive for at least one muscle marker in 77% (23/30) of cases; smooth muscle actin in 63% (17/27), calponin in 60% (6/10), SMMS-1 in 60% (3/5), desmin in 59% (16/27), muscle-specific actin in 40% (4/10), and caldesmon in 29% (2/7). The classical leiomyosarcoma component was often strongly positive for myogenic markers, and the pleomorphic sarcoma component usually showed focal and less intense immunoreactivity. Based on staining for muscle markers in the pleomorphic component, twenty-three cases were designated as pleomorphic leiomyosarcoma, and 7 cases were designated as dedifferentiated leiomyosarcoma (negative for all muscle markers used). Eleven cases, in which tissue was not available for immunhistochemical stains, the question of pleomorphic versus dedifferentiated leiomyosarcoma could not be answered. The incidence of metastasis was 89% (32/36) and the mortality rate was 50% (18/36) at last follow-up (3-104 months; mean, 27.5 months).</description><dc:title>Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases - Corrected Proof</dc:title><dc:creator>Marlo M. Nicolas, Pheroze Tamboli, Jose A. Gomez, Bogdan A. Czerniak</dc:creator><dc:identifier>10.1016/j.humpath.2009.10.005</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-11</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-11</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003049/abstract?rss=yes"><title>Papillary squamous intraepithelial lesions of the uterine cervix: human papillomavirus-dependent changes in cell cycle expression and cytologic features - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003049/abstract?rss=yes</link><description>Summary: Most human papillomavirus–associated squamous intraepithelial lesions of the uterine cervix are flat; some have papillary architecture that shows a spectrum of differentiation from low-grade squamous intraepithelial lesions to high-grade squamous intraepithelial lesions. For this subset of lesions, there are few data relating human papillomavirus type to cytology and cell cycle activity. Here, we collected 24 cases of papillary squamous intraepithelial lesions with either low-risk (15 cases) or high-risk (9 cases) human papillomavirus infection. We described their morphology and performed immunohistochemical staining with cell cycle–related markers Ki-67, p53, pRb, and P16INK4a. The Ki-67 labeling index was significantly lower in the low-risk group than in the high-risk group (P &lt; .001). A cut point of less than 50% labeling index detected all but one low-risk group case. Degradation of p53 and pRb was less evident in the low-risk group than in the high-risk group (p53, P &lt; .001; pRb, P = .006). P16INK4a produced an unexpectedly high positive rate of staining in the low-risk group (60%). However, a specific top-heavy distribution pattern was noted, with evident nuclear but faint cytoplasmic staining, whereas the high-risk group showed strong full-thickness nuclear and cytoplasmic staining. The detection of these lesions by smear examination was not reliable, given the wide expression pattern. Papillary structure was evident in none. We conclude that cell cycle–related markers are helpful in distinguishing low- and high-risk lesions. The strong p16INK4a staining in the low-risk group may imply that more cell cycle–controlling pressure is elicited in papillary lesions than in flat lesions. The distribution pattern of p16INK4a staining is important when making a diagnosis; cytology is not effective. Human papillomavirus type, histology, and cell cycle markers could clearly separate these lesions into either a low-risk or a high-risk group, properly designated low-grade squamous intraepithelial lesions or high-grade squamous intraepithelial lesions in current management algorithms. Thus, the previously used terms papillary immature metaplasia and immature condyloma, although descriptive for low-risk group lesions, are confusing and should be discarded.</description><dc:title>Papillary squamous intraepithelial lesions of the uterine cervix: human papillomavirus-dependent changes in cell cycle expression and cytologic features - Corrected Proof</dc:title><dc:creator>Cher-Wei Liang, Ming-Chieh Lin, Chen-Hsiang Hsiao, Yi-Ting Lin, Kuan-Ting Kuo</dc:creator><dc:identifier>10.1016/j.humpath.2009.05.015</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003190/abstract?rss=yes"><title>Glioblastoma with signet-ring morphology: a case report and review of the literature - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003190/abstract?rss=yes</link><description>Summary: Primary central nervous system tumors with signet-ring morphology are exceedingly rare. We report an unusual case of glioblastoma with signet-ring cell features in an 81-year-old woman. Microscopic examination revealed a highly anaplastic tumor, with a prominent proportion of tumor cells exhibiting signet-ring appearance characterized by classic round cytoplasmic inclusions and eccentrically positioned nuclei. The tumor cells were immunoreactive for glial fibrillary acidic protein and S100, and negative for cytokeratins, confirming their glial origin. Ultrastructurally, the tumor cells were noted to contain intermediate filaments, and by fluorescence in-situ hybridization analysis, they demonstrated intact 1p/19q. The presence of signet-ring cells in the central nervous system should immediately raise the suspicion of metastatic carcinoma, particularly from the upper gastrointestinal tract. In the present case, however, the morphological and immunohistochemical features were diagnostic of a malignant primary glial neoplasm (glioblastoma). This case highlights the diagnostic difficulties that can arise in such instances, given the rarity of signet-ring morphology in primary central nervous system tumors.</description><dc:title>Glioblastoma with signet-ring morphology: a case report and review of the literature - Corrected Proof</dc:title><dc:creator>Sarah E. Martin, Jose M. Bonnin, David C. Hall, Eyas M. Hattab</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.017</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>CASE STUDY</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003207/abstract?rss=yes"><title>Abnormal expression of telomerase/apoptosis limits type II alveolar epithelial cell replication in the early remodeling of usual interstitial pneumonia/idiopathic pulmonary fibrosis - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003207/abstract?rss=yes</link><description>Summary: Idiopathic pulmonary fibrosis is a distinctive, usually fatal, type of chronic fibrosing interstitial pneumonia of unknown cause that increases in prevalence with advanced age, characterized by failure of alveolar re-epithelization and progressive scar formation. Recently, limitation of the replicative capacity of tissues determined by telomerase/apoptosis balance has been implicated in pathogenesis of age-related diseases. In this study, we validated the importance of the expression of type 2 alveolar epithelial cells telomerase protein and studied the relationships between telomerase and apoptosis in early remodeling of usual interstitial pneumonia. We determined type 2 alveolar epithelial cells density, telomerase expression, and apoptosis in surgical lung biopsies from 24 patients with usual interstitial pneumonia, and in normal lung tissues from 18 subjects. We used immunohistochemistry, deoxynucleotidyl transferase method of end labeling, electron microscopy, and histomorphometry to evaluate the amount of type 2 alveolar epithelial cells staining for surfactant-A, telomerase, and in situ detection of apoptotic cells. Unaffected areas of usual interstitial pneumonia and normal lung tissue had similar densities of type 2 alveolar epithelial cells, but a significant minor subpopulation of type 2 alveolar epithelial cells was telomerase positive and a large population was telomerase negative. A significant inverse association was found between low type 2 alveolar epithelial cell telomerase expression and high apoptosis in unaffected areas of usual interstitial pneumonia. Although type 2 alveolar epithelial cell telomerase expression was higher than apoptosis in NLT group, no significant association was found between them. Electron microscopy confirmed epithelial apoptosis, alveolar collapse, and initial fibroplasia. We conclude that abnormal type 2 alveolar epithelial cells telomerase/apoptosis balance may reduce alveolar epithelial regenerative capacity, thus contributing to the early remodeling response in usual interstitial pneumonia.</description><dc:title>Abnormal expression of telomerase/apoptosis limits type II alveolar epithelial cell replication in the early remodeling of usual interstitial pneumonia/idiopathic pulmonary fibrosis - Corrected Proof</dc:title><dc:creator>Daniel Reis Waisberg, João Valente Barbas-Filho, Edwin Roger Parra, Sandra Fernezlian, Carlos Roberto Ribeiro de Carvalho, Ronaldo Adib Kairalla, Vera Luiza Capelozzi</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.019</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS004681770900327X/abstract?rss=yes"><title>PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS004681770900327X/abstract?rss=yes</link><description>Summary: The increased expression of PDZ binding kinase/lymphokine-activated killer T-cell–originated protein kinase (PBK/TOPK) is associated with some human malignant tumors. In this study, we analyzed PBK/TOPK expression in hepatic primary tumor and explored its role in cholangiocarcinoma biology. Seventy-four cholangiocarcinomas, 33 hepatocellular carcinomas, and 10 normal liver tissues were prepared from paraffin-embedded specimens. PBK/TOPK protein was assessed by immunohistochemical staining, and the survival time was analyzed with the Kaplan-Meier method. The protein, mRNA of PBK/TOPK, and cell cycle of cholangiocarcinoma cell line after PBK/TOPK suppression with small interfere RNA were studied by Western blot, semiquantitative reverse transcriptase–polymerase chain reaction, and flow cytometry, respectively. PBK/TOPK was usually expressed in normal bile duct epithelial cells and much more frequently expressed in cholangiocarcinoma (68/74) but never expressed in hepatocytes and hepatocellular carcinomas (0/33). PBK/TOPK down-regulation was related to the poor prognosis of patients with cholangiocarcinoma (P = .013). Epidermal growth factor can enhance PBK/TOPK expression in cholangiocarcinoma QBC 939 cells, but suppression of PBK/TOPK in the cells did not affect their proliferation. PBK/TOPK protein could serve as a useful indicator for histopathologic differentiation between cholangiocarcinoma and hepatocellular carcinomas and the low expression of PBK/TOPK is predicative of poor survival in cholangiocarcinoma patients.</description><dc:title>PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma - Corrected Proof</dc:title><dc:creator>Furong He, Qingguo Yan, Linni Fan, Yixiong Liu, Jihong Cui, Juanhong Wang, Lu Wang, Yingmei Wang, Zhe Wang, Ying Guo, Gaosheng Huang</dc:creator><dc:identifier>10.1016/j.humpath.2009.05.016</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003281/abstract?rss=yes"><title>End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003281/abstract?rss=yes</link><description>Summary: In a proportion of liver cirrhosis, the etiology continues to remain elusive. It is uncertain whether and to what extent cirrhosis evolving from nonalcoholic fatty liver disease contributes to this group of cryptogenic cirrhosis because the clinicopathologic features of nonalcoholic fatty liver disease cirrhosis are largely unknown. We explored these facets by examining the explant livers and clinical data in living donor liver transplant recipients. Among 103 adult liver transplant recipients with different types of chronic liver disease, 30 had a pre–liver transplant diagnosis of cryptogenic cirrhosis. A final categorization of the native liver disease was attempted in these cases on the basis of detail pathomorphological findings in adequately sampled explant liver correlated with careful review of pre–liver transplant clinical data. Of the 30 cryptogenic cirrhosis cases, 19 (63.3%) finally labeled as nonalcoholic fatty liver disease cirrhosis showed histologic features in several respects different from those reported for the early and established phases of nonalcoholic fatty liver disease. Steatosis was infrequent and focal or even absent, whereas variable grades of Mallory hyaline and inflammation were consistently present. Ductular proliferation and hydropic change of hepatocytes were also frequent. Only 9 (47%) of the 19 cases had nonalcoholic fatty liver disease associated risk factors like diabetes and obesity. It was concluded that appreciation of quantitative and qualitative differences in hepatic morphology between the cirrhotic and the early/established stage of nonalcoholic fatty liver disease will help in making a correct diagnosis of nonalcoholic fatty liver disease cirrhosis in the proper clinical setting. When appropriate criteria are used, nonalcoholic fatty liver disease appears to account for close to two thirds of cases currently labeled as cryptogenic cirrhosis.</description><dc:title>End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program - Corrected Proof</dc:title><dc:creator>Nabeen C. Nayak, Nandini Vasdev, Sanjiv Saigal, Arvinder S. Soin</dc:creator><dc:identifier>10.1016/j.humpath.2009.06.021</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003293/abstract?rss=yes"><title>The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003293/abstract?rss=yes</link><description>Summary: Cervical lymph node metastases from unknown primary sites account for approximately 3% to 9% of all head and neck malignant lesions. Squamous cell carcinoma is the most common type of cervical metastatic carcinoma. Our aim was to investigate the possibility of determining the site of primary tumors using an immunohistochemical diagnostic panel in metastatic cervical lymph nodes. Expression profiles of cytokeratins, 5/6; 8/18; 10; 13; 14; and 19, p16, and pRb were evaluated in 101 consecutive patients with cervical nodal metastasis who had undergone neck dissection to treat known head and neck squamous cell carcinoma (primary sites: 16, oral cavity; 38, oropharynx; 26, hypopharynx; 21, larynx). Cytokeratin 10 was more frequently expressed in oral cavity primary tumors, whereas cytokeratin 19 staining was more frequently observed in tumors originated from the pharynx and larynx. The expression of p16 and altered pRb status (0% or &gt;50%) were more frequently observed in oropharynx primary tumors. To select the best subset among the 8 antibodies tested, classification and regression tree analysis was performed. The analysis correctly classified the four primary sites (25.0% of oral cavity, 89.5% of oropharynx, 30.8% of hypopharynx, and 57.1% of larynx) using 5 variables (histologic subtype, p16, cytokeratins 10 and 19, and pRb). The p16 was the single best predictor. The classification tree method using immunostaining profiles of p16, cytokeratins 10 and 19, or pRb may be helpful in the identification of the primary site of metastatic squamous cell carcinoma with occult primary.</description><dc:title>The use of an immunohistochemical diagnostic panel to determine the primary site of cervical lymph node metastases of occult squamous cell carcinoma - Corrected Proof</dc:title><dc:creator>Jung Mee Park, Chan Kwon Jung, Yeong Jin Choi, Kyo Young Lee, Jin Hyoung Kang, Min Sik Kim, Hae Jin Hu</dc:creator><dc:identifier>10.1016/j.humpath.2009.09.001</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003335/abstract?rss=yes"><title>Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003335/abstract?rss=yes</link><description>Summary: Mucinous nonneoplastic cyst of the pancreas is a newly described and rare cystic lesion with unknown histogenesis. It is defined as a cystic lesion lined with mucinous epithelium, supported by hypocellular stroma and not communicating with the pancreatic ducts. It is very challenging to differentiate this lesion from other cystic mucinous neoplasms of the pancreas such as branch-duct intraductal papillary mucinous neoplasm by morphology. In this study, a total of 436 pancreatic specimens resected between 2002 and 2007 in our institution were reviewed. Fifteen (3.4%, 15/436) mucinous nonneoplastic cysts were identified. They included 3 males and 12 females, with a median age of 60 years. Forty-six percent of cases (7/15) occurred in pancreatic head, 27% (4/15) in neck, 7% (1/15) in body, and 20% (3/15) in tail. The size of lesions ranged from 0.5 to 3.5 cm in greatest dimension. In most cases (12/15, 80%), mucinous nonneoplastic cyst was associated or adjacent to acinar-ductal mucinous metaplasia. These morphologic data indicate that mucinous nonneoplastic cyst is not really a rare disease and may originate from acinar-duct mucinous metaplasia histogenestically. Furthermore, apomucin immunostains of mucinous nonneoplastic cyst showed MUC1 expressed in 27% (4/15) cases, MUC5AC in 67% (10/15 cases), and MUC2 was were negative in all cases, whereas intraductal papillary mucinous neoplasm (n = 17; 5 main duct type, 12 branch-duct type) showed focal and weak MUC1 positivity in 18% (3/17) cases, MUC2 positivity in 71% (12/17) cases, and all intraductal papillary mucinous neoplasm (17/17) were MUC5AC positive. The clonality assay with the HUMARA gene revealed that the mucinous nonneoplastic cysts were of polyclonal origin. For the first time, using HUMARA assay, we demonstrate the nonneoplastic nature of these cysts and further characterize morphologic and immunophenotypic properties that allow differentiation from intraductal papillary mucinous neooplasm.</description><dc:title>Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm - Corrected Proof</dc:title><dc:creator>Wenqing Cao, Brain P. Adley, Jie Liao, Xiaoqi Lin, Mark Talamonti, David J. Bentrem, Sambasiva M. Rao, Guang-Yu Yang</dc:creator><dc:identifier>10.1016/j.humpath.2009.05.017</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-12-02</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-12-02</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709002925/abstract?rss=yes"><title>Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709002925/abstract?rss=yes</link><description>Summary: In the currently published World Health Organization-Classification, the new entity of Epstein-Barr virus–positive diffuse large B-cell lymphoma of the elderly was introduced largely based on findings from East-Asian populations. Little is known about its frequency or characteristics in the West, especially in European populations. Using a tissue microarray approach, we identified 8 out of 258 diffuse large B-cell lymphoma cases fulfilling the World Health Organization criteria of an Epstein-Barr virus–positive diffuse large B-cell lymphoma of the elderly, suggesting an incidence of 3.1% in a European population. The median patient age was 65 years. The highest diagnostic sensitivity was only achieved by EBER in situ hybridization. No correlation between Epstein-Barr virus status and outcome was noted except in latency type 3 lymphomas, which had a very poor survival. Sixty-seven percent of Epstein-Barr virus–positive cases showed the presence of necrosis and 50% expressed the activation marker CD30. However, no morphological or immunohistochemical features reliably distinguished all Epstein-Barr virus–positive diffuse large B-cell lymphoma cases. Thus, to identify these Epstein-Barr virus–positive diffuse large B-cell lymphoma in the elderly, EBER in situ hybridization of all de novo diffuse large B-cell lymphoma cases of patients older than 50 years should be considered. In summary, Epstein-Barr virus–positive diffuse large B-cell lymphoma of the elderly is rare in Europeans older than 50 years. It can only be diagnosed by EBER-ISH, and its precise prognostic role is unclear. Whether routine testing of all diffuse large B-cell lymphoma patients older than 50 years can be recommended depends essentially on its clinical relevance. Future studies are needed to address this question.</description><dc:title>Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations - Corrected Proof</dc:title><dc:creator>Sylvia Hoeller, Alexandar Tzankov, Stefano A. Pileri, Philip Went, Stephan Dirnhofer</dc:creator><dc:identifier>10.1016/j.humpath.2009.07.024</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-11-16</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-11-16</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003189/abstract?rss=yes"><title>Desmoplastic small round cell tumor of the submandibular gland—a rare but distinctive primary salivary gland neoplasm - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003189/abstract?rss=yes</link><description>Summary: Desmoplastic small round cell tumor is a highly aggressive neoplasm that generally involves the peritoneum and pelvis of young patients. Only rare cases occur outside the abdomen. We report a case presenting as a primary submandibular gland tumor in a 24-year-old man. Histologically, although there were irregular tumor islands lying in an abundant desmoplastic stroma, there were also areas comprising large cellular islands with scanty stroma in between, raising the differential diagnosis of various salivary gland carcinomas. The tumor cells were medium sized, with hyperchromatic nuclei and moderate amounts of cytoplasm. The diagnosis of desmoplastic small round cell tumor was confirmed by the presence of a polyphenotypic immunoprofile (positive for cytokeratin, desmin, and neuron-specific enolase) and the characteristic EWS-WT1 gene fusion. Although rare, desmoplastic small round cell tumor has to be considered in the differential diagnosis of poorly differentiated neoplasms of the salivary gland, especially in young patients.</description><dc:title>Desmoplastic small round cell tumor of the submandibular gland—a rare but distinctive primary salivary gland neoplasm - Corrected Proof</dc:title><dc:creator>Wei-Hua Yin, Shuang-Ping Guo, Hong-Yu Yang, John K.C. Chan</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.015</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-11-16</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-11-16</prism:publicationDate><prism:section>CASE STUDY</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003220/abstract?rss=yes"><title>Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and “triple-negative” breast cancers - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003220/abstract?rss=yes</link><description>Summary: Basal-like carcinomas and human epidermal growth factor receptor 2 (HER-2/neu) overexpression carcinomas are the subgroups of breast cancers that have the most aggressive clinical behavior. Phosphorylation/activation of c-Jun NH2-terminal kinase is characterized as a stress-activated protein kinase, which regulates apoptosis after cellular stress. The aim of this study was to evaluate the association of phosphorylated c-Jun NH2-terminal kinase expression with phenotypes and clinicopathologic parameters of breast cancer. Phosphorylated c-Jun NH2-terminal kinase was immunohistochemically measured in a cohort of 160 patients with invasive breast cancer treated with therapeutic surgery followed by anthracycline or docetaxel-based chemotherapy. These results were further correlated with the phenotypes and clinicopathologic characteristics of breast cancers. Increased phosphorylated c-Jun NH2-terminal kinase expression was significantly associated with lack of estrogen receptor expression (P &lt; .0001), positivity for cytokeratins 5/6 (P = .029), epidermal growth factor receptor (P = .035), basal-like phenotype (P = .015), and “triple-negative” phenotype (P = .01). Furthermore, the positive expression of phosphorylated c-Jun NH2-terminal kinase was positively correlated with p-glycoprotein (r = 0.54, P &lt; .0001) and multidrug resistance–associated protein 1(r = 0.38, P &lt; .0001) but not with lung resistance protein (r = −0.02, P = .78). Our results indicate that the activation of phosphorylated c-Jun NH2-terminal kinase may play a role in the carcinogenesis of basal-like and triple-negative breast carcinoma.</description><dc:title>Elevated expression of phosphorylated c-Jun NH2-terminal kinase in basal-like and “triple-negative” breast cancers - Corrected Proof</dc:title><dc:creator>Xiao Wang, Lan Chao, Xin Li, Guohui Ma, Liansheng Chen, Yixiu Zang, Gengyin Zhou</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.018</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-11-16</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-11-16</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709003232/abstract?rss=yes"><title>Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709003232/abstract?rss=yes</link><description>Summary: Angiosarcoma of the skin is an extremely rare malignant tumor of vascular origin that usually arises in the scalp and face of elderly persons. To clarify its characteristic features and cell cycle kinetics, we quantitatively evaluated the expression of cell cycle–related molecules and vascular endothelial growth factors using immunohistochemical staining, for comparison with 2 benign vascular tumors of the skin, the capillary hemangioma and the cavernous hemangioma. Cell proliferation, determined with reference to the Ki-67 labeling index, was highest in angiosarcomas and lowest in cavernous hemangiomas (angiosarcomas versus capillary hemangioma, P = .014; capillary hemangioma versus cavernous hemangiomas, P = 1.4 × 10−4). Similar differences were also found in cyclin A, cyclin E, and p21Waf1 expression. Expressions of cyclin D1 and p16INK4A were also significantly higher in angiosarcoma than in cavernous hemangioma. Expressions of these 5 proteins showed significant positive correlations with Ki-67 labeling indices (Spearman ρ = 0.91-0.43). Expression levels of vascular endothelial growth factor and its receptor, VEGFR-2, were highest in angiosarcomas. VEGF-C expression in angiosarcomas was significantly higher than in cavernous hemangiomas, and its receptor VEGFR-3 expression was highest in angiosarcomas. Furthermore, significant positive correlations of these protein expression with Ki-67 labeling indices were noted (Spearman ρ = 0.88-0.40). Among them, VEGFR-3 showed the highest correlation coefficient. These results suggest that not only VEGFR-2-mediated signal but also VEGFR-3-mediated signal may contribute to proliferation of vascular tumor cells as autocrine and paracrine signaling factors.</description><dc:title>Autocrine and paracrine roles of VEGF/VEGFR-2 and VEGF-C/VEGFR-3 signaling in angiosarcomas of the scalp and face - Corrected Proof</dc:title><dc:creator>Wataru Tokuyama, Tetuo Mikami, Mikio Masuzawa, Isao Okayasu</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.021</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-11-16</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-11-16</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item><item rdf:about="http://www.humanpathol.com/article/PIIS0046817709002883/abstract?rss=yes"><title>Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma - Corrected Proof</title><link>http://www.humanpathol.com/article/PIIS0046817709002883/abstract?rss=yes</link><description>Summary: Low-grade chondrosarcoma and enchondroma are occasionally difficult to differentiate solely by reference to clinicoradiologic and histologic findings. The A disintegrin and metalloproteinases are a new gene family of proteins having a metalloprotease domain with matrix metalloproteinases and play an important role in the chondrocyte development process. Therefore, we analyzed the expression of A disintegrin and metalloproteinases and matrix metalloproteinases in several kinds of cartilaginous bone tumors at the messenger RNA level and immunohistochemical protein level and ascertained their relationships to the histologic degree of malignancy. Reverse transciptase-polymerase chain reaction and real-time quantitative reverse transciptase-polymerase chain reaction of the expression of the A disintegrin and metalloproteinase family in cartilaginous bone tumors demonstrated that A disintegrin and metalloproteinase 28 messenger RNA levels in grade I chondrosarcoma were significantly higher than those in enchondroma (P = .009). Moreover, positive immunoreactivity of A disintegrin and metalloproteinase 28 was observed in 12 (59%) of 22 patients with grade I chondrosarcoma and in 21 (91%) of 23 patients with grade II chondrosarcoma, respectively. In contrast, only 2 (9%) of 21 cases of enchondromas demonstrated positive staining for A disintegrin and metalloproteinase 28. On the other hand, the immunohistochemical expressions of matrix metalloproteinase 9 and matrix metalloproteinase 13 were significantly higher in enchondromas than in normal cartilage tissue; however, there is no statistically different expression between enchondromas and grade I chondrosarcomas. We detected that overexpression of A disintegrin and metalloproteinase 28 was increased according to its histologic grade in conventional chondrosarcoma and could be one of the helpful tools in distinguishing between low-grade chondrosarcoma and enchondroma.</description><dc:title>Overexpression of A disintegrin and metalloproteinase 28 is correlated with high histologic grade in conventional chondrosarcoma - Corrected Proof</dc:title><dc:creator>Suguru Matsuura, Yoshinao Oda, Hiroshi Matono, Teiyu Izumi, Hidetaka Yamamoto, Sadafumi Tamiya, Yukihide Iwamoto, Masazumi Tsuneyoshi</dc:creator><dc:identifier>10.1016/j.humpath.2009.08.002</dc:identifier><dc:source>Human Pathology (2009)</dc:source><dc:date>2009-11-09</dc:date><prism:publicationName>Human Pathology</prism:publicationName><prism:publicationDate>2009-11-09</prism:publicationDate><prism:section>ORIGINAL CONTRIBUTION</prism:section></item></rdf:RDF>